Abstract
3569 Background: Changes in tumor size using WHO RECIST-criteria have been extensively employed to monitor palliative chemotherapy and describe objective treatment response (OR). Few have questioned the fixed thresholds for response evaluation, particularly using RECIST and the relevance of an OR for patient prognosis is unclear. The aim was to determine whether the magnitude of change in tumor size at the first follow-up CT-examination after baseline examination (first change) correlates with outcome in patients with metastatic colorectal cancer (mCRC) treated with combination chemotherapy. Methods: The first change was retrospectively analyzed in a multicenter randomized phase III trial (Nordic VI, n=567) comparing first-line irinotecan with either bolus or infused 5-FU. Cox proportional hazards multiple regression model and Kaplan-Meier survival analyses after correction for guarantee-time bias were performed to evaluate correlations between first change, OR according to RECIST 1.0, progression-free su...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.